Tanshinone IIA pretreatment attenuates hepatic ischemia-reperfusion.

@article{Qi2012TanshinoneIP,
  title={Tanshinone IIA pretreatment attenuates hepatic ischemia-reperfusion.},
  author={Yan-yan Qi and Liang Xiao and Lu-ding Zhang and Sh Song and Yi Mei and Teng Chen and Jian-ming Tang and Fang Liu and Guoshan Ding and Yong-zhao Shi and Quanxing Wang},
  journal={Frontiers in bioscience},
  year={2012},
  volume={4},
  pages={
          1303-13
        }
}
Tanshinone IIA (Tan IIA), an active component derived from Salvia miltiorrhiza root, has been used to treat various ischemic cardiovascular and cerebrovascular diseases. However, its impact on hepatic ischemia/reperfusion (I/R) injury remains unclear. Here, we addressed this issue by using a 90-minute partial liver ischemia model. Mice were administered Tan IIA intragastrically for 3 days before ischemia and were assessed for liver damage 6-h after reperfusion. Tan IIA pretreatment… 

Figures from this paper

Tanshinone IIA pretreatment attenuates ischemia/reperfusion-induced renal injury.

The present results suggest that tanshinone IIA pretreatment attenuates I/RIRI via the downregulation of MPO expression, inflammation, MIF, cleaved caspase-3 and p38 MAPK.

Tanshinone IIA protects against acetaminophen-induced hepatotoxicity via activating the Nrf2 pathway.

Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1[S]

It is demonstrated that a novel HO-1-dependent mechanism is involved in the regulation of cholesterol balance by Tan, which reduces the content of macrophages, cholesterol accumulation, and the development of atherosclerotic plaque in apolipoprotein E-deficient mice.

Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats.

It is indicated that STS prevents pulmonary arterial hypertension development likely by inhibiting TRPC1 and TRPC6 expression, resulting in normalized basal [Ca(2+)](i) and attenuated proliferation and migration of PASMCs.

The Protective Effect of Traditional Chinese Medicine on Liver Ischemia-Reperfusion Injury

The results indicate that TCMs attenuate liver I/R injury via multiple mechanisms, including antioxidation stress, anti-inflammatory response, antiapoptosis, and inhibiting endoplasmic reticulum stress.

Preventive and therapeutic role of Tanshinone ⅡA in hepatology.

References

SHOWING 1-10 OF 38 REFERENCES

Addition of tanshinone IIA to UW solution decreases skeletal muscle ischemia-reperfusion injury

UW and UW+T prevented luxury perfusion during reperfusion and inhibited ICAM-1 expression and apoptosis after 6-h reperfusions, suggesting that tanshinone IIA has clinical value.

Heme Oxygenase-1 Mediated Cytoprotection Against Liver Ischemia and Reperfusion Injury: Inhibition of Type-1 Interferon Signaling

Evidence is provided for a novel mechanism by which HO-1 exerts adaptive cytoprotective and anti-inflammatory functions in the context of innate TLR4 activation during liver IRI, which decreases CXCL-10 production.

The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion

It is demonstrated that HMGB1 is an early mediator of injury and inflammation in liver I/R and implicates TLR4 as one of the receptors that is involved in the process.

Toll‐like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury

Improvements in liver function inTLR4KO HFD animals implicate TLR4 as a mediator of steatotic graft failure after I/R, and removal of endotoxin before reperfusion improves liver performance post‐I/R.

Endogenous A1 adenosine receptors protect against hepatic ischemia reperfusion injury in mice

  • Jeehee KimMihwa KimJoseph H. SongH. Lee
  • Biology, Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2008
It is concluded that endogenous A1AR activation prevents worsened murine liver IR injury primarily by reducing necrotic and apoptotic cell death, and may lead to new therapies for perioperative hepatic IR injury.